Appco Pharma LLC
Appco Pharma LLC lists 9 drug products in the FDA National Drug Code directory.
Products
| NDC | Product | Strength | Type |
|---|---|---|---|
| 55801-187 | Clomiphene Citrate Tablet | Clomiphene Citrate 50 mg/1 | Rx |
| 55801-527 | Doxepin Hydrochloride Capsule | Doxepin Hydrochloride 10 mg/1 | Rx |
| 55801-528 | Doxepin Hydrochloride Capsule | Doxepin Hydrochloride 25 mg/1 | Rx |
| 55801-529 | Doxepin Hydrochloride Capsule | Doxepin Hydrochloride 50 mg/1 | Rx |
| 55801-530 | Doxepin Hydrochloride Capsule | Doxepin Hydrochloride 75 mg/1 | Rx |
| 55801-531 | Doxepin Hydrochloride Capsule | Doxepin Hydrochloride 100 mg/1 | Rx |
| 55801-338 | Sildenafil Tablet | Sildenafil Citrate 25 mg/1 | Rx |
| 55801-339 | Sildenafil Tablet | Sildenafil Citrate 50 mg/1 | Rx |
| 55801-340 | Sildenafil Tablet | Sildenafil Citrate 100 mg/1 | Rx |
Recalls by Appco Pharma LLC
- D-0421-2026 Apr 8, 2026 · Class II
cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits. - D-0420-2026 Apr 8, 2026 · Class II
cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits. - D-0419-2026 Apr 8, 2026 · Class II
cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits. - D-0208-2025 Jan 29, 2025 · Class III
Failed Tablet/Capsule Specifications: Missing tab ID on either side of the tablet - D-0649-2020 Jan 15, 2020 · Class II
CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API - D-0648-2020 Jan 15, 2020 · Class II
CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API